Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

Phase 2

Not yet recruiting

• Conditions: Locally Advanced Gastric Cancer
• Interventions: Drug: Camrelizumab; Drug: Oxaliplatin; Drug: S1; Drug: Apatinib Mesylate; Drug: Nab paclitaxel

• Registration Number: NCT05524974
• Lead Sponsor: Fujian Medical University

Brief Summary

To evaluate the clinical efficacy of camrelizumab, apatinib Mesylate and nab-paclitaxel combined with oxplatin and S-1 in the neoadjuvant treatment of locally advanced gastric cancer with different genotypes

Detailed Description

Not available

Study Timeline

• Status Verified: 2022-08
• Study First Submitted: 2022-08-10
• Study First Submitted QC: 2022-08-30
• Last Update Submitted: 2022-08-30
• Study Start: 2022-09-01
• Study First Posted: 2022-09-01
• Last Update Posted: 2022-09-01
• Primary Completion: 2024-09-01
• Study Completion: 2027-09-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 203

Inclusion Criteria

1. Age from 18 to 75 years, all sex；

2. Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by histology or cytology；

3. CT/MRI,PET-CT or laparoscopic exploration were used to confirm the diagnosis of gastric cancer staging as cT2-4a and/or N+ and M0 before operation.；

4. measurable lesions at least should be detected by CT/MRI examination in accordance with the RECIST1.1.（CT scan of tumor lesion length≥10mm，CT scan short diameter of lymph node≥15mm，scan slice thickness 5mm）;

5. ECOG（Eastern Cooperative Oncology Group）PS（Performance Status）:0-1 scores;

6. the expected survival time is more than 12 weeks;

7. the main organ function is normal, which should meet the following criteria: （1）(1)blood routine examination standards should be met（no blood transfusion within 14 days）

   1. HB≥100g/L，
   2. WBC≥3×109/L
   3. ANC≥1.5×109/L，
   4. PLT≥100×109/L； （2）biochemical examination shall comply with the following criteria：
   <!-- -->
   1. BIL <1.5normal upper limit（ULN），
   2. ALT和AST<2.5ULN，GPT≤1.5×ULN；
   3. serum Cr≤1ULN，creatinine clearance rate>60ml/min（Cockcroft-Gault formula）

8. women of childbearing age must have a pregnancy test in 7 days before entering the group (in serum), and the results were negative, and willing to use appropriate contraception during the study period and the last 8 weeks after giving drug; men should have the surgical sterilization, or adopt the appropriate contraceptive methods during the test and the last 8 weeks after giving drug.；

9. No other clinical studies were conducted before and during the treatment； participants is willing to participate in this study, sign the informed consent, have good compliance, cooperate with follow-up.

Exclusion Criteria

1. Previous history of chemotherapy, radiotherapy, targeted drug therapy or immunotherapy
2. Patients with contraindications for surgical treatment and chemotherapy or whose physical condition and organ function do not allow for major abdominal surgery；
3. patients with metastasis；
4. Having any active autoimmune diseases or a history of autoimmune diseases (such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes); Patients with vitiligo or cured childhood asthma/allergies who did not need any intervention in adulthood were excluded; Autoimmune hypothyroidism treated with a stable dose of thyroid replacement hormone; Type 1 diabetes with stable doses of insulin；
5. A history of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency disorders, or a history of organ transplantation and allogeneic bone marrow transplantation；
6. Accompanied by serious heart, lung, liver, kidney disease; Have nerve, mental disease; Jaundice or obstruction of the digestive tract with severe infection；
7. pregnant or lactating women；
8. The blood pressure of patients with hypertension cannot be reduced to the normal range by the antihypertensive drugs (systolic pressure >140 mmHg, diastolic pressure >90 mmHg)；
9. With Ⅰ magnitude of coronary heart disease, arrhythmia (including QTc protracted between male > 450 ms, women > 470 ms) and cardiac insufficiency；
10. Patients have a clear tendency with gastrointestinal bleeding, including the following situation: local active ulcerative lesions, and fecal occult blood (+ +); with melena and hematemesis history in 2 months; and patients with fecal occult blood (+) and coagulation dysfunction (INR(international normalized ratio)>1.5, APTT(activated partial thromboplastin time)>1.5 ULN), with bleeding tendency;；
11. Subjects have failed to control good cardiovascular clinical symptoms or disease, including but not limited to: such as: (1) the NYHA class II heart failure or above (2) unstable angina pectoris (3) MI occurred within 1 year (4) have clinical significance of supraventricular or ventricular arrhythmias without clinical intervention on or after clinical intervention is still poorly controlled；
12. History of interstitial lung disease (except radiation pneumonia without hormone therapy), and history of non-infectious pneumonia；
13. Patients are positive of urine protein (urine protein detection 2+ or above, or 24 hours urine protein quantitative >1.0g)；
14. A person who has previously been allergic to any component of the drug in this study； The researchers consider those who were not suitable for inclusion.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Camrelizumab combined with Oxplatin and S-1 for Immune Genotypes	Oxaliplatin	-
Camrelizumab combined with Oxplatin and S-1 for Immune Genotypes	S1	-
Oxplatin and S-1 for Immune Genotypes	S1	-
Apatinib Mesylate combined with Oxplatin and S-1 for Mesenchymal Genotypes	S1	-
Apatinib Mesylate combined with Oxplatin and S-1 for Mesenchymal Genotypes	Apatinib Mesylate	-
Camrelizumab combined with Oxplatin and S-1 for Immune Genotypes	Camrelizumab	-
Oxplatin and S-1 for Mesenchymal Genotypes	S1	-
Nab-paclitaxel combined with Oxplatin and S-1 for Classic Genotypes	Nab paclitaxel	-
Oxplatin and S-1 for Classic Genotypes	Oxaliplatin	-
Oxplatin and S-1 for Classic Genotypes	S1	-
Oxplatin and S-1 for Metabolic Genotypes	Oxaliplatin	-
Nab-paclitaxel combined with Oxplatin and S-1 for Classic Genotypes	S1	-
Oxplatin and S-1 for Metabolic Genotypes	S1	-
Oxplatin and S-1 for Immune Genotypes	Oxaliplatin	-
Apatinib Mesylate combined with Oxplatin and S-1 for Mesenchymal Genotypes	Oxaliplatin	-
Oxplatin and S-1 for Mesenchymal Genotypes	Oxaliplatin	-
Nab-paclitaxel combined with Oxplatin and S-1 for Classic Genotypes	Oxaliplatin	-

Primary Outcome Measures

Name	Time	Method
Objective response rate	4 months	Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST

Secondary Outcome Measures

Name	Time	Method
30 days mortality rates	30 days	Defined as the event observed within 30 days after surgery.
R0 resection rate	4 months	The surgical procedure was total or subtotal gastrectomy with 3 weeks after total neoadjuvant therapy.
overall postoperative morbidity rates	30 days	Refers to the incidence of early postoperative complications. The early postoperative complication are defined as the event observed within 30 days after surgery.
Duration of postoperative hospital stay	30 days	Duration of postoperative hospital stay in days is used to assess the postoperative recovery course.
The prediction performance of Exosome contents (including proteins, nucleic acids)	3 years	Exosomes were isolated using a Backman Optima XPN-100 instrument. The exosomes morphology was characterized using a HT7700 transmission electron microscope (Hitachi, Co. Ltd., Japan). Fluorescent spectra were recorded using a F96 Pro fluorospectrophotometer (Shanghai Lengguang Technology). The concentration and size distribution of the exosomes were quantified using nanoparticle tracking analysis (NanoSight NS 300, Malvern Instrument). The obtained results were subjected to biostatistical analysis, such as heat map generation, ROC curve establishment, and confusion matrix.
Disease control rate	4 months
1-year and 3-year OS/DFS	1 and 3 years
adverse event	3 years	An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

Trial Locations

Locations (1)

Fujian Medical University Union Hospital; 🇨🇳 Fuzhou, Fujian, China